Session V: Hepatocellular Cancer

O-16: HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)

Anca-Ligia Grosu

The study authors note that the final safety and efficacy results of the HEPANOVA trial are currently under final analyses. their hypothesis is that treatment with Tumor Treating Fields (TTFields, 150 kHz) as a novel modality for HCC will be efficacious and safe in the treatment of advanced HCC.


O-1: Results from a global Phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

Ghassan K. Abou-Alfa

The study authors demonstrated with Tislelizumab durable responses. The treatment was well tolerated in patients with previously systemically treated unresectable HCC, a patient population with a continued high unmet medical need.